AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01356225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
Study NCT01356225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN placebo
Study NCT02266810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROPEL Mini Sinus Implant.
Description: Placement of sinus implant following frontal sinus surgery
Study NCT02266810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Surgery alone
Description: Sinus surgery only, without implant placement
Study NCT02266810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propel Nova Sinus Implant
Description: Placement of sinus implant following frontal sinus surgery
Study NCT00404079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
Study NCT00404079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
Study NCT03678116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (placebo)
Description: Taken orally in capsule form
Study NCT03678116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine (plus Teacrine and Cayenne)
Description: Taken orally in capsule form
Study NCT03678116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine (plus Teacrine)
Description: Taken orally in capsule form
Study NCT06135831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional olive paste
Description: Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
Study NCT06135831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calciovitmag (CDCaMg)
Description: Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
Study NCT01052779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study NCT06135831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosporovitmag (PDCaMg)
Description: Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
Study NCT06135831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
Study NCT02648425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
Study NCT01052779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: IV Iron Sucrose
Study NCT02648425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + capecitabine
Description: Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
Study NCT02648425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + 5-fluorouracil (or+ Leucovorin)
Description: Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
Study NCT01723670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day for 24 months
Study NCT01723670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 2x, once a day for 24 months
Study NCT01723670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet,once a day for 24 months
Study NCT00624546 — intervention group
Intervention type: DRUG
Intervention: Prevacid Solutabs
Description: BID Prevacid Solutabs
Study NCT00624546 — intervention group
Intervention type: PROCEDURE
Intervention: Antireflux surgery
Description: Lap Nissen
Study NCT03433261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
Study NCT03452306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformine
Description: First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition
Study NCT03452306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® Long
Description: Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition
Study NCT03452306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition
Study NCT03452306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® Long
Description: Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition
Study NCT01506362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7040
Description: BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days.
Study NCT04408287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WebEx Physical Activity Program
Description: The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
Study NCT05507047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Protein
Description: Enamel matrix derivated is used with transcrestal sinus lifting treatment
Study NCT05507047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Protein
Description: Enamel matrix derivated is used with transcrestal sinus lifting treatment
Study NCT02485158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALC
Description: This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Study NCT02485158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
Study NCT02485158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
Study NCT00005087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00005087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00005087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00005087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00005087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01398202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: 20 micrograms per day for 10 weeks
Study NCT01398202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25-hydroxyvitamin D3
Description: 7 microgram/day for 10 weeks
Study NCT01398202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25-hydroxyvitamin D (20 microgram/day)
Description: 20 microgramday for 10 weeks
Study NCT01398202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
Study NCT00692315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (methylB12)
Description: 75 ug/Kg methylB12 every 3 days by subcutaneous injection
Study NCT00502593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
Study NCT02247076 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Grazing
Study NCT01349088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive capecitabine at 2000 mg/m2.
Study NCT01349088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motesanib
Description: Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
Study NCT01442454 — intervention group
Intervention type: OTHER
Intervention: chronic pancreatitis
Description: No intervention, subjects followed through surgery
Study NCT02247076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (early eating)
Study NCT01422928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical Acupuncture
Description: Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported.
Study NCT00503113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg intravenous (iv) injection every 3 months
Study NCT00503113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg intravenous (iv) infusion every 3 months
Study NCT00503113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70mg per oral (po) weekly
Study NCT03507686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB111
Description: Administered as specified in the treatment arm.
Study NCT04402918 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biological samples day of delivery
Description: mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
Study NCT01237821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BenzaClin
Description: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
Study NCT01237821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effaclar
Description: Topical, Bid, 12 weeks
Study NCT00502593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: 2 doses, intramuscular injection on Days 0 and 21.
Study NCT04035512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004.
Study NCT00493623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. single dose
Study NCT00493623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg i.v. single dose
Study NCT03299270 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Quality of Life and Functional recovery questionnaires
Study NCT04292769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 10mg / d, intravenous administration d-5 ～ d-1
Study NCT04292769 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-CIK
Description: Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
Study NCT04292769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
Study NCT02288598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: 20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
Study NCT02288598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency Training
Description: Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
Study NCT02288598 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fluency Training
Description: Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
Study NCT01612104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid
Description: A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
Study NCT04027829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
Study NCT00589901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and cyclophosphamide
Description: capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14
Study NCT00286507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.
Description: Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
Study NCT04622306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Description: Condom functionality study to determine failure rates
Study NCT04622306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Description: Condom functionality study to determine failure rates
Study NCT02817074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIND Diet
Description: 3-year dietary counseling to adhere to the MIND diet and for mild weight loss
Study NCT02817074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mild Weight Loss
Description: 3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
Study NCT02817074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mild Weight Loss
Description: 3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
Study NCT02499276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV, NAVA, PAV, Variable-PSV
Description: Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
Study NCT02041767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: One single injection of 1g of ertapenem before surgery
Study NCT03897023 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gut Microbiota
Description: Status of microbiota
Study NCT01572350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grid laser
Description: Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
Study NCT01572350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
Study NCT01572350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
Study NCT01252381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12 weeks Strength exercise training
Description: Training 3 times a week, leg extensions and leg press
Study NCT01252381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks Strength exercise training
Description: Training 3 times a week, leg extensions and leg press
Study NCT02248831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recording Doppler ultrasound signals noninvasively
Description: Using ultrasound noninvasively and recording Doppler signals from the right chest wall
Study NCT03572244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-Lok
Description: A microgrooved abutment will be placed
Study NCT03572244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Machined
Description: A machined transmucosal healing abutment will be placed
Study NCT02520830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Group
Description: 22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
Study NCT02520830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
Study NCT01422460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)
Study NCT01061216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal insulin delivery: BD Research Catheter Set
Description: 1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
Study NCT01061216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set
Description: 1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)